aspirin has been researched along with Birth Weight in 67 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Daily aspirin, started in the first trimester of pregnancy, is commonly used for the prevention of preeclampsia and fetal growth restriction in multiple gestation." | 9.51 | Aspirin Responsiveness at a Dose of 80 mg and Its Impact on Birth Weight when Used in Twin Pregnancies: The GAP Pilot Randomized Trial. ( Boutin, A; Bujold, E; Camiré, B; Carpentier, C; Guerby, P; Tapp, S, 2022) |
| " The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage." | 9.41 | Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023) |
| "Preconception-initiated low-dose aspirin might positively affect pregnancy outcomes, but this possibility has not been adequately assessed." | 9.19 | Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. ( Faraggi, D; Galai, N; Lesher, LL; Lynch, AM; Mumford, SL; Perkins, NJ; Schisterman, EF; Silver, RM; Townsend, JM; Wactawski-Wende, J, 2014) |
| "To investigate whether low dose aspirin medication given to primiparous women provides benefit in preventing pre-eclampsia or intrauterine growth retardation." | 9.08 | A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group. ( Golding, J, 1998) |
| "The results of this study in Barbados do not support the routine use of low dose aspirin for prevention of pre-eclampsia or its complications, confirming results of previous large trials in other settings." | 9.08 | Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. ( Ayers, S; Collins, R; Cruickshank, JK; Duley, L; Farrell, B; Gay, MP; Grant, A; Griffiths, J; Hennis, A; Rotchell, YE; Stewart, A, 1998) |
| "To determine whether low-dose aspirin reduces the incidence of pre-eclampsia, reduces perinatal mortality and improves birth weights in pregnant women considered at high risk of developing pre-eclampsia." | 9.08 | A randomized controlled trial of low-dose aspirin in women at risk from pre-eclampsia. ( Byaruhanga, RN; Chipato, T; Rusakaniko, S, 1998) |
| "The purpose of this study was to investigate the hypothesis that maternal administration of 100mg aspirin each day will improve birth-weight and other measures of neonatal size when given as a treatment to pregnancies complicated by fetal growth restriction and umbilical-placental insufficiency." | 9.08 | Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial. ( Evans, SF; Godfrey, M; Newnham, JP; Phillips, J; Walters, BJ, 1995) |
| "The results of this study do not support the routine prophylactic administration of low dose aspirin in pregnancy to any category of high risk women (even those who have chronic hypertension or who are considered to be especially liable to early onset pre-eclampsia)." | 9.08 | ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group. ( , 1996) |
| " Whether patients were assigned to aspirin or placebo, birth weight was significantly greater in women who had a twofold or greater reduction in maternal serum thromboxane B2 levels." | 9.08 | Maternal serum thromboxane B2 reduction versus pregnancy outcome in a low-dose aspirin trial. ( Copper, RL; Cutter, GR; Goldenberg, RL; Hauth, JC; Parker, CR, 1995) |
| "A multicentric randomized double-blind trial was realized in order to determine whether a treatment with a low-dose aspirin (150 mg/day) with or without dipyridamole (225 mg/day) was able to prevent the perinatal consequences of pre-eclampsia." | 9.07 | Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group. ( Sureau, C, 1991) |
| "The efficacy of low-dose aspirin in preventing fetal growth retardation was tested in a randomised, placebo-controlled, double-blind trial." | 9.07 | Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. ( Bazin, B; Beaufils, M; Breart, G; Capitant, C; Paris, J; Uzan, S, 1991) |
| "Meta-analysis of data from several controlled trials has shown that low-dose aspirin reduces the risk of pregnancy-induced hypertension (PIH) and intrauterine growth retardation (IUGR) in women at high risk of these disorders." | 9.07 | Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. ( , 1993) |
| "A randomized, placebo-controlled, double-blind trial was carried out to evaluate the fetal benefits of low-dose aspirin (150 mg/day) as a treatment of placental insufficiency during the last trimester of pregnancy." | 9.06 | Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency. ( Connelly, A; Cook, CM; Giles, WB; Thompson, RS; Trudinger, BJ, 1988) |
| " Low-dose aspirin and dipyridamole direct prostacyclin/thromboxane A2 balance in pregnancy to the dominance of prostacyclin and may thus prevent idiopathic uteroplacental insufficiency and fetal growth retardation in high-risk patients." | 9.06 | Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. ( Rotmans, N; Wallenburg, HC, 1987) |
| "To determine in women with hereditary thrombophilia whether the use of the combination of low-molecular-weight heparin (LMWH) and aspirin (ASA) is better than ASA alone." | 8.93 | Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials. ( Areia, AL; Areia, M; Fonseca, E; Moura, P, 2016) |
| "In high-risk pregnancies, early aspirin intervention starting before 16 weeks of gestation can prevent PIH, preeclampsia, IUGR, and preterm birth and help to increase the birth weight." | 8.91 | [Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis]. ( Wu, H; Yao, S; Yu, Y, 2015) |
| "We assessed the effects and safety of aspirin treatment during pregnancy on fetal and neonatal outcomes." | 8.82 | Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. ( Boskovic, R; Costei, AM; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2003) |
| "Recent surveys of prenatal drug consumption indicate that aspirin is the most frequently consumed drug in pregnancy." | 8.75 | Aspirin in pregnancy: maternal and fetal effects. ( Corby, DG, 1978) |
| "To estimate whether low-dose aspirin use is associated with an altered risk of delivering a small-for-gestational age (SGA) neonate among women with a history of having an SGA neonate in a prior pregnancy." | 8.12 | Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy. ( Bergman, L; Cluver, CA; Hastie, R; Hesselman, S; Kupka, E; Lindquist, A; Tong, S; Walker, SP; Wikström, AK, 2022) |
| "Low dose Aspirin in pregnancy reduces the incidence of intra uterine growth retardation (IUGR) and pregnancy induced hypertension (PIH) in women at risk for these complications." | 7.68 | Low dose aspirin in pregnancy: a clinical and biochemical study of effects on the newborn. ( Foschini, M; Frusca, T; Soregaroli, M; Tarantini, M; Valcamonico, A, 1993) |
| " there was no evidence that aspirin taken in pregnancy is a cause of stillbirth, neonatal death, or reduced birth-weight." | 7.65 | Perinatal mortality and birth-weight in relation to aspirin taken during pregnancy. ( Heinonen, OP; Kaufman, DW; Monson, RR; Shapiro, S; Siskind, V; Slone, D, 1976) |
| "The main outcome was preeclampsia or a birthweight ≤ 5th percentile." | 7.11 | Low-dose aspirin to prevent preeclampsia and growth restriction in nulliparous women identified by uterine artery Doppler as at high risk of preeclampsia: A double blinded randomized placebo-controlled trial. ( Arthuis, C; Cheve, MT; Debarge, VH; Delmas, HL; Diguisto, C; Doret, M; Durin, L; Equy, V; Flandrin, A; Gallot, D; Giraudeau, B; Haddad, G; Le Gouge, A; Marchand, MS; Mares, P; Megier, P; Paumier, A; Perrotin, F; Schaub, B; Sentilhes, L; Vayssiere, C; Ville, Y; Winer, N, 2022) |
| "Aspirin was associated with a lower rate of late-onset preeclampsia ⩾34w (17." | 6.80 | Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU High-Risk Aspirin Study. ( Allshouse, AA; Galan, HL; Heyborne, KD; Moore, GS; Post, AL, 2015) |
| "Aspirin was not associated with a significant increase in placental haemorrhages or in bleeding during preparation for epidural anaesthesia, but there was a slight increase in use of blood transfusion after delivery." | 6.67 | CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. ( , 1994) |
| "Aspirin was also associated with a reduction in rates of spontaneous preterm birth (OR 0." | 6.42 | Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. ( Coomarasamy, A; Gee, H; Honest, H; Khan, KS; Papaioannou, S, 2003) |
| "This is a single site sub-study of data collected in conjunction with the Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) Trial, which is listed at ClinicalTrials." | 5.69 | Birth weight and gestational age distributions in a rural Kenyan population. ( Achieng, E; Bucher, S; Ekhaguere, OA; Esamai, FO; Kemboi, M; Liechty, EA; Marete, I; Nowak, K; Nyongesa, P; Otieno, K; Rutto, F; Tenge, C, 2023) |
| "Daily aspirin, started in the first trimester of pregnancy, is commonly used for the prevention of preeclampsia and fetal growth restriction in multiple gestation." | 5.51 | Aspirin Responsiveness at a Dose of 80 mg and Its Impact on Birth Weight when Used in Twin Pregnancies: The GAP Pilot Randomized Trial. ( Boutin, A; Bujold, E; Camiré, B; Carpentier, C; Guerby, P; Tapp, S, 2022) |
| " The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage." | 5.41 | Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023) |
| "Preconception-initiated low-dose aspirin might positively affect pregnancy outcomes, but this possibility has not been adequately assessed." | 5.19 | Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. ( Faraggi, D; Galai, N; Lesher, LL; Lynch, AM; Mumford, SL; Perkins, NJ; Schisterman, EF; Silver, RM; Townsend, JM; Wactawski-Wende, J, 2014) |
| "To compare the effect of aspirin and enoxaparin on live births in women with unexplained recurrent miscarriages, as well as secondary outcomes including birth weight, uterine and umbilical blood flows, and congenital malformations." | 5.12 | A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. ( Brenner, B; Carp, H; Dolitzky, M; Inbal, A; Segal, Y; Weiss, A, 2006) |
| "This was a prospective observation of pregnancy outcomes among 462 women with pregestational diabetes mellitus (White classes B-F) and singleton pregnancies who were enrolled in a multicenter trial to compare low-dose aspirin with placebo for preeclampsia prevention." | 5.09 | Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Dombrowski, M; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, M; MacPherson, C; McNellis, D; Meis, P; Miodovnik, M; Paul, R; Roberts, J; Sibai, BM; Thurnau, G; VanDorsten, JP, 2000) |
| " Whether patients were assigned to aspirin or placebo, birth weight was significantly greater in women who had a twofold or greater reduction in maternal serum thromboxane B2 levels." | 5.08 | Maternal serum thromboxane B2 reduction versus pregnancy outcome in a low-dose aspirin trial. ( Copper, RL; Cutter, GR; Goldenberg, RL; Hauth, JC; Parker, CR, 1995) |
| "Aspirin therapy increased birth weight in all women, especially in women with high human chorionic gonadotropin levels, partly by increasing gestational age at delivery." | 5.08 | The effect of low-dose aspirin on pregnancies complicated by elevated human chorionic gonadotropin levels. ( DuBard, MB; Goldenberg, RL; Hauth, JC; Lea, C; Wenstrom, KD, 1995) |
| "The results of this study do not support the routine prophylactic administration of low dose aspirin in pregnancy to any category of high risk women (even those who have chronic hypertension or who are considered to be especially liable to early onset pre-eclampsia)." | 5.08 | ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group. ( , 1996) |
| "The purpose of this study was to investigate the hypothesis that maternal administration of 100mg aspirin each day will improve birth-weight and other measures of neonatal size when given as a treatment to pregnancies complicated by fetal growth restriction and umbilical-placental insufficiency." | 5.08 | Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial. ( Evans, SF; Godfrey, M; Newnham, JP; Phillips, J; Walters, BJ, 1995) |
| "To determine whether low-dose aspirin reduces the incidence of pre-eclampsia, reduces perinatal mortality and improves birth weights in pregnant women considered at high risk of developing pre-eclampsia." | 5.08 | A randomized controlled trial of low-dose aspirin in women at risk from pre-eclampsia. ( Byaruhanga, RN; Chipato, T; Rusakaniko, S, 1998) |
| "The results of this study in Barbados do not support the routine use of low dose aspirin for prevention of pre-eclampsia or its complications, confirming results of previous large trials in other settings." | 5.08 | Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. ( Ayers, S; Collins, R; Cruickshank, JK; Duley, L; Farrell, B; Gay, MP; Grant, A; Griffiths, J; Hennis, A; Rotchell, YE; Stewart, A, 1998) |
| "To investigate whether low dose aspirin medication given to primiparous women provides benefit in preventing pre-eclampsia or intrauterine growth retardation." | 5.08 | A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group. ( Golding, J, 1998) |
| "Meta-analysis of data from several controlled trials has shown that low-dose aspirin reduces the risk of pregnancy-induced hypertension (PIH) and intrauterine growth retardation (IUGR) in women at high risk of these disorders." | 5.07 | Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. ( , 1993) |
| "The efficacy of low-dose aspirin in preventing fetal growth retardation was tested in a randomised, placebo-controlled, double-blind trial." | 5.07 | Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. ( Bazin, B; Beaufils, M; Breart, G; Capitant, C; Paris, J; Uzan, S, 1991) |
| "A multicentric randomized double-blind trial was realized in order to determine whether a treatment with a low-dose aspirin (150 mg/day) with or without dipyridamole (225 mg/day) was able to prevent the perinatal consequences of pre-eclampsia." | 5.07 | Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group. ( Sureau, C, 1991) |
| "A randomized, placebo-controlled, double-blind trial was carried out to evaluate the fetal benefits of low-dose aspirin (150 mg/day) as a treatment of placental insufficiency during the last trimester of pregnancy." | 5.06 | Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency. ( Connelly, A; Cook, CM; Giles, WB; Thompson, RS; Trudinger, BJ, 1988) |
| " Low-dose aspirin and dipyridamole direct prostacyclin/thromboxane A2 balance in pregnancy to the dominance of prostacyclin and may thus prevent idiopathic uteroplacental insufficiency and fetal growth retardation in high-risk patients." | 5.06 | Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. ( Rotmans, N; Wallenburg, HC, 1987) |
| "To determine in women with hereditary thrombophilia whether the use of the combination of low-molecular-weight heparin (LMWH) and aspirin (ASA) is better than ASA alone." | 4.93 | Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials. ( Areia, AL; Areia, M; Fonseca, E; Moura, P, 2016) |
| "In high-risk pregnancies, early aspirin intervention starting before 16 weeks of gestation can prevent PIH, preeclampsia, IUGR, and preterm birth and help to increase the birth weight." | 4.91 | [Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis]. ( Wu, H; Yao, S; Yu, Y, 2015) |
| "We assessed the effects and safety of aspirin treatment during pregnancy on fetal and neonatal outcomes." | 4.82 | Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. ( Boskovic, R; Costei, AM; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2003) |
| "Recent surveys of prenatal drug consumption indicate that aspirin is the most frequently consumed drug in pregnancy." | 4.75 | Aspirin in pregnancy: maternal and fetal effects. ( Corby, DG, 1978) |
| " Among SLE group, lower birth weight and smaller gestational age were observed in SLE mothers with disease active during pregnancy, kidney involved, blood system involved and not taking Aspirin during pregnancy." | 4.31 | Association of preterm outcome with maternal systemic lupus erythematosus: a retrospective cohort study. ( Bei, F; Bu, J; Chen, X; Di, W; Hu, Y; Jiang, M; Sun, J; Wu, J; Ye, L, 2023) |
| "To estimate whether low-dose aspirin use is associated with an altered risk of delivering a small-for-gestational age (SGA) neonate among women with a history of having an SGA neonate in a prior pregnancy." | 4.12 | Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy. ( Bergman, L; Cluver, CA; Hastie, R; Hesselman, S; Kupka, E; Lindquist, A; Tong, S; Walker, SP; Wikström, AK, 2022) |
| " Antecedents of mNEC included mother's identification as Black, consumption of aspirin during the pregnancy, and vaginal bleeding after the 12th week of gestation." | 3.83 | The antecedents and correlates of necrotizing enterocolitis and spontaneous intestinal perforation among infants born before the 28th week of gestation. ( Allred, EN; Grzybowski, M; Leviton, A; Martin, CR; Shah, B; Singh, R, 2016) |
| "This prospective study aimed to evaluate pregnancy outcome and complications in women with recurrent pregnancy loss (RPL) and protein S (PS) deficiency, who received low dose aspirin (LDA) or LDA plus heparin (LDA/H) therapies." | 3.83 | Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss. ( Deguchi, M; Ebina, Y; Morizane, M; Shinozaki, N; Tanimura, K; Yamada, H, 2016) |
| " This study aims to investigate whether calcium channel blockers plus low dosage aspirin therapy can reduce the incidence of complications during pregnancy with chronic hypertension and improve the prognosis of neonates." | 3.81 | The effect of calcium channel blockers on prevention of preeclampsia in pregnant women with chronic hypertension. ( Jiang, N; Liu, L; Liu, Q; Yang, WW; Zeng, Y, 2015) |
| "The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders." | 3.77 | Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. ( Bakhti, A; Vaiman, D, 2011) |
| " If thrombophilia was diagnosed on the basis of hyperhomocysteinemia, the treatment consisted of aspirin, pyridoxine and folic acid, instead." | 3.71 | Non-pregnant circulatory volume status predicts subsequent pregnancy outcome in normotensive thrombophilic formerly preeclamptic women. ( Aardenburg, R; de Leeuw, PW; Ekhart, TH; Peeters, LL; Spaanderman, ME; van der Heijden, OW; van Eyck, J; van Eyndhoven, HW, 2001) |
| " Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome." | 3.70 | Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000) |
| "Low dose Aspirin in pregnancy reduces the incidence of intra uterine growth retardation (IUGR) and pregnancy induced hypertension (PIH) in women at risk for these complications." | 3.68 | Low dose aspirin in pregnancy: a clinical and biochemical study of effects on the newborn. ( Foschini, M; Frusca, T; Soregaroli, M; Tarantini, M; Valcamonico, A, 1993) |
| ", malformation rates were similar in the children of 35 418 women not exposed to aspirin, 9736 with intermediate exposure, and 5128 women heavily exposed during the first four lunar months of pregnancy." | 3.65 | Aspirin and congenital malformations. ( Heinonen, OP; Kaufman, DW; Monson, RR; Shapiro, S; Siskind, V; Slone, D, 1976) |
| " there was no evidence that aspirin taken in pregnancy is a cause of stillbirth, neonatal death, or reduced birth-weight." | 3.65 | Perinatal mortality and birth-weight in relation to aspirin taken during pregnancy. ( Heinonen, OP; Kaufman, DW; Monson, RR; Shapiro, S; Siskind, V; Slone, D, 1976) |
| "The main outcome was preeclampsia or a birthweight ≤ 5th percentile." | 3.11 | Low-dose aspirin to prevent preeclampsia and growth restriction in nulliparous women identified by uterine artery Doppler as at high risk of preeclampsia: A double blinded randomized placebo-controlled trial. ( Arthuis, C; Cheve, MT; Debarge, VH; Delmas, HL; Diguisto, C; Doret, M; Durin, L; Equy, V; Flandrin, A; Gallot, D; Giraudeau, B; Haddad, G; Le Gouge, A; Marchand, MS; Mares, P; Megier, P; Paumier, A; Perrotin, F; Schaub, B; Sentilhes, L; Vayssiere, C; Ville, Y; Winer, N, 2022) |
| "Aspirin was significantly associated with a higher birthweight Z-score (0." | 2.84 | Impact of aspirin on fetal growth in diabetic pregnancies according to White classification. ( Adkins, K; Allshouse, AA; Heyborne, KD; Metz, TD, 2017) |
| "Aspirin was associated with a lower rate of late-onset preeclampsia ⩾34w (17." | 2.80 | Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU High-Risk Aspirin Study. ( Allshouse, AA; Galan, HL; Heyborne, KD; Moore, GS; Post, AL, 2015) |
| "Aspirin and heparin have been shown to have potentially beneficial effects on trophoblast implantation." | 2.79 | Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage. ( Adam, I; Ashur, BM; Elbareg, AM; Elmahashi, MO; Essadi, FM, 2014) |
| " Observations collected in two population pharmacokinetic studies, in preterm neonates, investigating amikacin and vancomycin were used to estimate: i) the impact of ibuprofen administration on the clearance of these drugs; and ii) the difference between prophylactic and therapeutic administration of ibuprofen on this clearance." | 2.72 | Impact of ibuprofen administration on renal drug clearance in the first weeks of life. ( Allegaert, K; Anderson, BJ; Rayyan, M, 2006) |
| "The reduction in the incidence of intrauterine growth retardation (2." | 2.70 | Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. ( Iso-Mustajärvi, M; Kujansuu, E; Mäenpää, J; Vainio, M, 2002) |
| "Aspirin was not associated with a significant increase in placental haemorrhages or in bleeding during preparation for epidural anaesthesia, but there was a slight increase in use of blood transfusion after delivery." | 2.67 | CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. ( , 1994) |
| "Aspirin was also associated with a reduction in rates of spontaneous preterm birth (OR 0." | 2.42 | Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. ( Coomarasamy, A; Gee, H; Honest, H; Khan, KS; Papaioannou, S, 2003) |
| " The teratogenic potential of a drug is related to dosage and time of administration." | 2.36 | Analgesics during pregnancy. ( Niederhoff, H; Zahradnik, HP, 1983) |
| "Toxemic pregnancy was the most common complication found in 9 patients." | 1.38 | [Successful completed pregnancies in patients with systemic lupus erythematosus]. ( Kiss, E; Szegedi, G; Tarr, T; Zeher, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (13.43) | 18.7374 |
| 1990's | 19 (28.36) | 18.2507 |
| 2000's | 12 (17.91) | 29.6817 |
| 2010's | 19 (28.36) | 24.3611 |
| 2020's | 8 (11.94) | 2.80 |
| Authors | Studies |
|---|---|
| Hastie, R | 1 |
| Tong, S | 1 |
| Wikström, AK | 1 |
| Walker, SP | 1 |
| Lindquist, A | 1 |
| Cluver, CA | 1 |
| Kupka, E | 1 |
| Bergman, L | 1 |
| Hesselman, S | 1 |
| Sielhorst, J | 1 |
| Roggel-Buecker, U | 1 |
| Neudeck, KC | 1 |
| Kahler, A | 1 |
| Rohn, K | 1 |
| Luettgenau, J | 1 |
| Bollwein, H | 1 |
| Hollinshead, F | 1 |
| Sieme, H | 1 |
| Diguisto, C | 1 |
| Le Gouge, A | 1 |
| Marchand, MS | 1 |
| Megier, P | 1 |
| Ville, Y | 1 |
| Haddad, G | 1 |
| Winer, N | 1 |
| Arthuis, C | 1 |
| Doret, M | 1 |
| Debarge, VH | 1 |
| Flandrin, A | 1 |
| Delmas, HL | 1 |
| Gallot, D | 1 |
| Mares, P | 2 |
| Vayssiere, C | 1 |
| Sentilhes, L | 1 |
| Cheve, MT | 1 |
| Paumier, A | 1 |
| Durin, L | 1 |
| Schaub, B | 1 |
| Equy, V | 1 |
| Giraudeau, B | 1 |
| Perrotin, F | 1 |
| D'Antonio, F | 3 |
| Khalil, A | 3 |
| Rizzo, G | 3 |
| Fichera, A | 3 |
| Herrera, M | 3 |
| Buca, D | 3 |
| Morelli, R | 3 |
| Cerra, C | 3 |
| Orabona, R | 3 |
| Acuti Martellucci, C | 3 |
| Flacco, ME | 3 |
| Prefumo, F | 3 |
| Bucher, S | 1 |
| Nowak, K | 1 |
| Otieno, K | 1 |
| Tenge, C | 1 |
| Marete, I | 1 |
| Rutto, F | 1 |
| Kemboi, M | 1 |
| Achieng, E | 1 |
| Ekhaguere, OA | 1 |
| Nyongesa, P | 1 |
| Esamai, FO | 1 |
| Liechty, EA | 1 |
| Chen, X | 1 |
| Di, W | 1 |
| Ye, L | 1 |
| Hu, Y | 1 |
| Jiang, M | 1 |
| Wu, J | 1 |
| Bu, J | 1 |
| Sun, J | 1 |
| Bei, F | 1 |
| Carpentier, C | 1 |
| Guerby, P | 1 |
| Camiré, B | 1 |
| Tapp, S | 1 |
| Boutin, A | 1 |
| Bujold, E | 1 |
| Adkins, K | 1 |
| Allshouse, AA | 2 |
| Metz, TD | 1 |
| Heyborne, KD | 2 |
| Ali, MK | 1 |
| Abbas, AM | 1 |
| Yosef, AH | 1 |
| Bahloul, M | 1 |
| Stanescu, AD | 1 |
| Banica, R | 1 |
| Sima, RM | 1 |
| Ples, L | 1 |
| Wang, X | 1 |
| Gao, H | 1 |
| Elmahashi, MO | 1 |
| Elbareg, AM | 1 |
| Essadi, FM | 1 |
| Ashur, BM | 1 |
| Adam, I | 1 |
| Schisterman, EF | 1 |
| Silver, RM | 1 |
| Lesher, LL | 1 |
| Faraggi, D | 1 |
| Wactawski-Wende, J | 1 |
| Townsend, JM | 1 |
| Lynch, AM | 1 |
| Perkins, NJ | 1 |
| Mumford, SL | 1 |
| Galai, N | 1 |
| Moussa, HN | 1 |
| Wu, ZH | 1 |
| Han, Y | 1 |
| Pacheco, LD | 1 |
| Blackwell, SC | 1 |
| Sibai, BM | 3 |
| Saade, G | 1 |
| Costantine, MM | 1 |
| Mutlu, I | 1 |
| Mutlu, MF | 1 |
| Biri, A | 1 |
| Bulut, B | 1 |
| Erdem, M | 1 |
| Erdem, A | 1 |
| Moore, GS | 1 |
| Post, AL | 1 |
| Galan, HL | 1 |
| Jiang, N | 1 |
| Liu, Q | 1 |
| Liu, L | 1 |
| Yang, WW | 1 |
| Zeng, Y | 1 |
| Abheiden, C | 1 |
| Van Hoorn, ME | 1 |
| Hague, WM | 1 |
| Kostense, PJ | 1 |
| van Pampus, MG | 1 |
| de Vries, J | 1 |
| Areia, AL | 1 |
| Fonseca, E | 1 |
| Areia, M | 1 |
| Moura, P | 1 |
| Yao, S | 1 |
| Wu, H | 1 |
| Yu, Y | 1 |
| Shinozaki, N | 1 |
| Ebina, Y | 1 |
| Deguchi, M | 1 |
| Tanimura, K | 1 |
| Morizane, M | 1 |
| Yamada, H | 1 |
| Singh, R | 1 |
| Shah, B | 1 |
| Allred, EN | 1 |
| Grzybowski, M | 1 |
| Martin, CR | 1 |
| Leviton, A | 1 |
| Neykova, K | 1 |
| Dimitrova, V | 1 |
| Dimitrov, R | 1 |
| Vakrilova, L | 1 |
| Roumi, JE | 1 |
| Moukhadder, HM | 1 |
| Graziadei, G | 1 |
| Pennisi, M | 1 |
| Cappellini, MD | 1 |
| Taher, AT | 1 |
| Bakhti, A | 1 |
| Vaiman, D | 1 |
| Grau, AJ | 1 |
| Howard, G | 1 |
| Tarr, T | 1 |
| Kiss, E | 1 |
| Szegedi, G | 1 |
| Zeher, M | 1 |
| Coomarasamy, A | 1 |
| Honest, H | 1 |
| Papaioannou, S | 1 |
| Gee, H | 1 |
| Khan, KS | 1 |
| Kozer, E | 1 |
| Costei, AM | 1 |
| Boskovic, R | 1 |
| Nulman, I | 1 |
| Nikfar, S | 1 |
| Koren, G | 1 |
| Gris, JC | 1 |
| Mercier, E | 1 |
| Quéré, I | 1 |
| Lavigne-Lissalde, G | 1 |
| Cochery-Nouvellon, E | 1 |
| Hoffet, M | 1 |
| Ripart-Neveu, S | 1 |
| Tailland, ML | 1 |
| Dauzat, M | 1 |
| Allegaert, K | 2 |
| Anderson, BJ | 2 |
| Cossey, V | 1 |
| Holford, NH | 1 |
| Goel, N | 1 |
| Tuli, A | 1 |
| Choudhry, R | 1 |
| Dolitzky, M | 1 |
| Inbal, A | 1 |
| Segal, Y | 1 |
| Weiss, A | 1 |
| Brenner, B | 2 |
| Carp, H | 2 |
| Rayyan, M | 1 |
| Niederhoff, H | 1 |
| Zahradnik, HP | 1 |
| Wenstrom, KD | 1 |
| Hauth, JC | 2 |
| Goldenberg, RL | 2 |
| DuBard, MB | 1 |
| Lea, C | 1 |
| Parker, CR | 1 |
| Copper, RL | 1 |
| Cutter, GR | 1 |
| Valcamonico, A | 1 |
| Foschini, M | 1 |
| Soregaroli, M | 1 |
| Tarantini, M | 1 |
| Frusca, T | 1 |
| McGlone, JJ | 1 |
| Nicholson, RI | 1 |
| Hellman, JM | 1 |
| Herzog, DN | 1 |
| Ngo, VU | 1 |
| Cynober, E | 1 |
| Kammoun, M | 1 |
| Bouzaghar, A | 1 |
| Saranti, L | 1 |
| Jeny, R | 1 |
| Newnham, JP | 1 |
| Godfrey, M | 1 |
| Walters, BJ | 1 |
| Phillips, J | 1 |
| Evans, SF | 1 |
| Byaruhanga, RN | 1 |
| Chipato, T | 1 |
| Rusakaniko, S | 1 |
| Rotchell, YE | 1 |
| Cruickshank, JK | 1 |
| Gay, MP | 1 |
| Griffiths, J | 1 |
| Stewart, A | 2 |
| Farrell, B | 1 |
| Ayers, S | 1 |
| Hennis, A | 1 |
| Grant, A | 1 |
| Duley, L | 1 |
| Collins, R | 1 |
| Golding, J | 1 |
| Sullivan, MH | 1 |
| Clark, NA | 1 |
| de Swiet, M | 1 |
| Nelson-Piercy, C | 1 |
| Elder, MG | 1 |
| McCowan, LM | 1 |
| Harding, J | 1 |
| Roberts, A | 1 |
| Barker, S | 1 |
| Ford, C | 1 |
| Caritis, S | 1 |
| Hauth, J | 1 |
| Lindheimer, M | 1 |
| VanDorsten, JP | 1 |
| MacPherson, C | 1 |
| Klebanoff, M | 1 |
| Landon, M | 1 |
| Miodovnik, M | 1 |
| Paul, R | 1 |
| Meis, P | 1 |
| Dombrowski, M | 1 |
| Thurnau, G | 1 |
| Roberts, J | 1 |
| McNellis, D | 1 |
| Hoffman, R | 1 |
| Blumenfeld, Z | 1 |
| Weiner, Z | 1 |
| Younis, JS | 1 |
| Spaanderman, ME | 1 |
| Aardenburg, R | 1 |
| Ekhart, TH | 1 |
| van Eyndhoven, HW | 1 |
| van der Heijden, OW | 1 |
| van Eyck, J | 1 |
| de Leeuw, PW | 1 |
| Peeters, LL | 1 |
| Vainio, M | 1 |
| Kujansuu, E | 1 |
| Iso-Mustajärvi, M | 1 |
| Mäenpää, J | 1 |
| Soriano, D | 1 |
| Seidman, DS | 1 |
| Schiff, E | 1 |
| Langevitz, P | 1 |
| Mashiach, S | 1 |
| Dulitzky, M | 1 |
| Slone, D | 2 |
| Siskind, V | 2 |
| Heinonen, OP | 2 |
| Monson, RR | 2 |
| Kaufman, DW | 2 |
| Shapiro, S | 2 |
| Tanigawa, H | 1 |
| Obori, R | 1 |
| Tanaka, H | 1 |
| Yoshida, J | 1 |
| Kosazuma, T | 1 |
| Corby, DG | 1 |
| Uzan, S | 1 |
| Beaufils, M | 1 |
| Breart, G | 1 |
| Bazin, B | 1 |
| Capitant, C | 1 |
| Paris, J | 1 |
| Davies, NJ | 1 |
| Farquharson, RG | 1 |
| Walkinshaw, Sa | 1 |
| Fay, TN | 1 |
| Sureau, C | 1 |
| Trudinger, BJ | 1 |
| Cook, CM | 1 |
| Thompson, RS | 1 |
| Giles, WB | 1 |
| Connelly, A | 1 |
| Wallenburg, HC | 1 |
| Rotmans, N | 1 |
| Cunningham, MD | 1 |
| Ellison, RC | 1 |
| Zierler, S | 1 |
| Kanto, WP | 1 |
| Miettinen, OS | 1 |
| Nadas, AS | 1 |
| Lewis, RB | 1 |
| Schulman, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Transplacental Aspirin Therapy for Early Onset Fetal Growth[NCT04557475] | Phase 3 | 0 participants (Actual) | Interventional | 2022-06-11 | Withdrawn (stopped due to We are modifying this trial's protocol and will resubmit a new application at a later date.) | ||
| Low Dose Aspirin and Low-molecular-weight Heparin in the Treatment of Pregnant Libyan Women With Recurrent Miscarriage[NCT01917799] | Phase 4 | 150 participants (Anticipated) | Interventional | 2009-01-31 | Recruiting | ||
| The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.[NCT00467363] | 1,228 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial[NCT05253781] | Phase 3 | 476 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | ||
| Serum Assessment of Preterm Birth: Outcomes Compared to Historical Controls[NCT03151330] | 2,110 participants (Anticipated) | Interventional | 2018-06-15 | Active, not recruiting | |||
| Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study[NCT04908982] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-05-28 | Recruiting | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Partial or complete abruption (ie, premature separation of the placenta) (NCT00467363)
Timeframe: until delivery
| Intervention | participants (Number) |
|---|---|
| Aspirin | 7 |
| Placebo | 5 |
(NCT00467363)
Timeframe: 8-weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 374 |
| Placebo | 346 |
Implantation failures (NCT00467363)
Timeframe: 8 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 28 |
| Placebo | 27 |
(NCT00467363)
Timeframe: within 6 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 3 |
| Placebo | 3 |
(NCT00467363)
Timeframe: until 40 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 4 |
| Placebo | 6 |
(NCT00467363)
Timeframe: within 8-weeks of gestation
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 394 |
| Placebo | 363 |
Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff . (NCT00467363)
Timeframe: after delivery
| Intervention | livebirths (Number) |
|---|---|
| Aspirin | 309 |
| Placebo | 286 |
(NCT00467363)
Timeframe: 8 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 0 |
| Placebo | 0 |
(NCT00467363)
Timeframe: until delivery
| Intervention | participants (Number) |
|---|---|
| Aspirin | 32 |
| Placebo | 30 |
Includes preembryonic and embryonic losses (exclusive of implantation failures) (NCT00467363)
Timeframe: less than 10-weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 56 |
| Placebo | 53 |
(NCT00467363)
Timeframe: until delivery
| Intervention | infants (Number) |
|---|---|
| Aspirin | 22 |
| Placebo | 31 |
birthweight (NCT00467363)
Timeframe: until delivery
| Intervention | grams (Mean) |
|---|---|
| Aspirin | 3327 |
| Placebo | 3315 |
(NCT00467363)
Timeframe: 40 weeks
| Intervention | participants (Number) |
|---|---|
| Aspirin | 2 |
| Placebo | 2 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
9 reviews available for aspirin and Birth Weight
| Article | Year |
|---|---|
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Prevention of preeclampsia in high-risk patients with low-molecular-weight heparin: a meta-analysis.
Topics: Anticoagulants; Aspirin; Birth Weight; Female; Heparin, Low-Molecular-Weight; Humans; Placenta; Pre- | 2020 |
Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials.
Topics: Abortion, Habitual; Anticoagulants; Aspirin; Birth Weight; Female; Gestational Age; Heparin, Low-Mol | 2016 |
[Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis].
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Pre-Eclampsia; Pre | 2015 |
Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review.
Topics: Aspirin; Birth Weight; Female; Humans; Infant Mortality; Infant, Newborn; Infant, Premature; Obstetr | 2003 |
Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis.
Topics: Abnormalities, Drug-Induced; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Birth Weight; | 2003 |
Analgesics during pregnancy.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Birth Weight; Female; Fetal Death; | 1983 |
Aspirin in pregnancy: maternal and fetal effects.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Birth Weight; Cleft Lip; Cleft Palate; Female; Fetal | 1978 |
An aspirin a day to prevent prematurity.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Health Status Indicators; Humans; Obstetric | 1992 |
34 trials available for aspirin and Birth Weight
| Article | Year |
|---|---|
Effect of Acetylsalicylic Acid on Uterine Blood Flow, Gestation Length, Foal Birth Weight and Placental Weight in Pregnant Thoroughbred Mares - A Clinical Pilot Study.
Topics: Animals; Aspirin; Birth Weight; Female; Horses; Parturition; Pilot Projects; Placenta; Placental Cir | 2022 |
Low-dose aspirin to prevent preeclampsia and growth restriction in nulliparous women identified by uterine artery Doppler as at high risk of preeclampsia: A double blinded randomized placebo-controlled trial.
Topics: Aspirin; Birth Weight; Female; Humans; Infant, Newborn; Male; Pre-Eclampsia; Pregnancy; Pregnancy Tr | 2022 |
Birth weight and gestational age distributions in a rural Kenyan population.
Topics: Age Distribution; Aspirin; Birth Weight; Female; Gestational Age; Humans; Infant; Infant, Newborn; I | 2023 |
Aspirin Responsiveness at a Dose of 80 mg and Its Impact on Birth Weight when Used in Twin Pregnancies: The GAP Pilot Randomized Trial.
Topics: Aspirin; Birth Weight; Female; Humans; Infant, Newborn; Pilot Projects; Platelet Aggregation Inhibit | 2022 |
Impact of aspirin on fetal growth in diabetic pregnancies according to White classification.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Development; Fetal Macrosomia; Humans; Infant, Newborn; | 2017 |
The effect of low-dose aspirin on fetal weight of idiopathic asymmetrically intrauterine growth restricted fetuses with abnormal umbilical artery Doppler indices: a randomized clinical trial.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Platelet Aggregation Inhibit | 2018 |
Low dose aspirin for preventing fetal growth restriction: a randomised trial.
Topics: Adult; Aspirin; Birth Weight; Drug Administration Schedule; Female; Fetal Growth Retardation; Gestat | 2018 |
Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage.
Topics: Abortion, Habitual; Adult; Aspirin; Birth Weight; Embryo Implantation; Enoxaparin; Female; Fibrinoly | 2014 |
Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Birth Weight; Double-Blind Method; Drug Adm | 2014 |
Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Birth Weight; Double-Blind Method; Drug Adm | 2014 |
Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Birth Weight; Double-Blind Method; Drug Adm | 2014 |
Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Birth Weight; Double-Blind Method; Drug Adm | 2014 |
Customized versus Population Fetal Growth Norms and Adverse Outcomes Associated with Small for Gestational Age Infants in a High-Risk Cohort.
Topics: Aspirin; Birth Weight; Cesarean Section; Cyclooxygenase Inhibitors; Female; Fetal Development; Fetal | 2015 |
Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU High-Risk Aspirin Study.
Topics: Adult; Aspirin; Birth Weight; Female; Gestational Age; Humans; Infant, Newborn; Pre-Eclampsia; Pregn | 2015 |
Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results.
Topics: Adult; Anticoagulants; Aspirin; Birth Weight; Blood Flow Velocity; Drug Therapy, Combination; Female | 2016 |
Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder.
Topics: Aspirin; Birth Weight; Enoxaparin; Female; Fetal Death; Folic Acid; Heparin, Low-Molecular-Weight; H | 2004 |
The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies.
Topics: Abortion, Habitual; Adult; Antibodies, Anticardiolipin; Anticoagulants; Apgar Score; Aspirin; Birth | 2006 |
A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages.
Topics: Abortion, Habitual; Abortion, Induced; Adult; Anticoagulants; Aspirin; Birth Rate; Birth Weight; Eno | 2006 |
Impact of ibuprofen administration on renal drug clearance in the first weeks of life.
Topics: Age Factors; Amikacin; Anti-Bacterial Agents; Aspirin; Betamethasone; Birth Weight; Cyclooxygenase I | 2006 |
The effect of low-dose aspirin on pregnancies complicated by elevated human chorionic gonadotropin levels.
Topics: Adolescent; Adult; Aspirin; Birth Weight; Chi-Square Distribution; Chorionic Gonadotropin; Double-Bl | 1995 |
Maternal serum thromboxane B2 reduction versus pregnancy outcome in a low-dose aspirin trial.
Topics: Aspirin; Birth Weight; Double-Blind Method; Embryonic and Fetal Development; Female; Humans; Obstetr | 1995 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy.
Topics: Adolescent; Adult; Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; P | 1993 |
ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group.
Topics: Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Follow-Up Studies; Humans; Obs | 1996 |
Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial.
Topics: Adult; Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Placent | 1995 |
Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial.
Topics: Adult; Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Placent | 1995 |
Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial.
Topics: Adult; Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Placent | 1995 |
Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial.
Topics: Adult; Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Placent | 1995 |
A randomized controlled trial of low-dose aspirin in women at risk from pre-eclampsia.
Topics: Adult; Aspirin; Birth Weight; Confidence Intervals; Dose-Response Relationship, Drug; Female; Follow | 1998 |
Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications.
Topics: Adult; Aspirin; Barbados; Birth Weight; Delayed-Action Preparations; Female; Fetal Death; Gestationa | 1998 |
A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group.
Topics: Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Follow-Up Studies; Hum | 1998 |
Administration of low-dose aspirin to mothers with small for gestational age fetuses and abnormal umbilical Doppler studies to increase birthweight: a randomised double-blind controlled trial.
Topics: Adult; Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Platele | 1999 |
Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
Topics: Aspirin; Birth Weight; Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; | 2000 |
Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches.
Topics: Adult; Arteries; Aspirin; Birth Weight; Blood Flow Velocity; Double-Blind Method; Female; Fetal Grow | 2002 |
Management and outcome of pregnancy in women with thrombophylic disorders and past cerebrovascular events.
Topics: Adult; Anticoagulants; Aspirin; Birth Weight; Cerebrovascular Disorders; Cohort Studies; Female; Fib | 2002 |
Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial.
Topics: Adult; Aspirin; Birth Weight; Dipyridamole; Double-Blind Method; Drug Administration Schedule; Drug | 1991 |
Low-dose aspirin and nulliparae.
Topics: Aspirin; Birth Weight; Cesarean Section; Double-Blind Method; Female; Fetal Growth Retardation; Huma | 1991 |
Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group.
Topics: Abruptio Placentae; Aspirin; Birth Weight; Dipyridamole; Double-Blind Method; Drug Combinations; Fem | 1991 |
Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency.
Topics: Adult; Aspirin; Birth Weight; Blood Flow Velocity; Clinical Trials as Topic; Double-Blind Method; Fe | 1988 |
Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole.
Topics: Adult; Aspirin; Birth Weight; Clinical Trials as Topic; Dipyridamole; Epoprostenol; Female; Fetal Gr | 1987 |
24 other studies available for aspirin and Birth Weight
| Article | Year |
|---|---|
Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy.
Topics: Aspirin; Birth Weight; Cohort Studies; Female; Fetal Growth Retardation; Gestational Age; Humans; In | 2022 |
Association of preterm outcome with maternal systemic lupus erythematosus: a retrospective cohort study.
Topics: Aspirin; Birth Weight; Child; China; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Lup | 2023 |
Effects of anticoagulant therapy on pregnancy outcomes in patients with thrombophilia and previous poor obstetric history.
Topics: Abortion, Habitual; Anticoagulants; Apgar Score; Aspirin; Birth Weight; Blood Coagulation Factors; D | 2015 |
The effect of calcium channel blockers on prevention of preeclampsia in pregnant women with chronic hypertension.
Topics: Adult; Amlodipine; Aspirin; Birth Weight; Blood Pressure; Calcium Channel Blockers; China; Female; H | 2015 |
Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Aspirin; Birth Weight; Comorbidity; Drug Th | 2016 |
The antecedents and correlates of necrotizing enterocolitis and spontaneous intestinal perforation among infants born before the 28th week of gestation.
Topics: Adult; Aspirin; Birth Weight; Enterocolitis, Necrotizing; Female; Gestational Age; Humans; Infant, N | 2016 |
[ANTITHROMBOTIC MEDICATION IN PREGNANT WOMEN WITH PREVIOUS INTRAUTERINE GROWTH RESTRICTION].
Topics: Anticoagulants; Aspirin; Birth Weight; Female; Fetal Growth Retardation; Gestational Age; Heparin, L | 2016 |
Pregnancy in β-thalassemia intermedia at two tertiary care centers in Lebanon and Italy: A follow-up report on fetal and maternal outcomes.
Topics: Abortion, Habitual; Abortion, Spontaneous; Aspirin; beta-Thalassemia; Birth Weight; Cesarean Section | 2017 |
Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation.
Topics: Adult; Aspirin; Birth Weight; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Fetal | 2011 |
Advances in stroke: population studies.
Topics: Aspirin; Birth Weight; Circadian Rhythm; Diet; Humans; Life Style; Motor Activity; Population Survei | 2012 |
[Successful completed pregnancies in patients with systemic lupus erythematosus].
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Azathioprine; Birth Weight; Female; Follow-Up Studies; Gest | 2012 |
Limited predictability of amikacin clearance in extreme premature neonates at birth.
Topics: Age Factors; Amikacin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bact | 2006 |
Low dose aspirin in pregnancy: a clinical and biochemical study of effects on the newborn.
Topics: Aspirin; Birth Weight; Cerebral Hemorrhage; Female; Fetal Blood; Fetal Growth Retardation; Gestation | 1993 |
The development of pain in young pigs associated with castration and attempts to prevent castration-induced behavioral changes.
Topics: Age Factors; Analgesia; Animals; Animals, Newborn; Aspirin; Behavior, Animal; Birth Weight; Butorpha | 1993 |
[Retroplacental hematoma and uterine Doppler scan].
Topics: Adult; Aspirin; Birth Weight; Blood Flow Velocity; Diagnosis, Differential; Diastole; Female; Hemato | 1993 |
Titration of antiplatelet treatment in pregnant women at risk of preeclampsia.
Topics: Abortion, Spontaneous; Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; | 1998 |
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Topics: 3' Untranslated Regions; Abortion, Habitual; Activated Protein C Resistance; Adult; Anticoagulants; | 2000 |
Non-pregnant circulatory volume status predicts subsequent pregnancy outcome in normotensive thrombophilic formerly preeclamptic women.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Folic Acid; Gestational Age; HELLP Syndrome | 2001 |
Aspirin and congenital malformations.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Aspirin; Birth Weight; Female; Humans; Infant, | 1976 |
Perinatal mortality and birth-weight in relation to aspirin taken during pregnancy.
Topics: Aspirin; Birth Weight; Black People; Female; Fetal Death; Humans; Infant, Newborn; Infant, Newborn, | 1976 |
[Reproduction study of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101) in rats (II). Administration of M73101 during the period of major organogenesis (author's transl)].
Topics: Abnormalities, Drug-Induced; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Behavior, An | 1979 |
Low-dose aspirin during pregnancy.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Pregnancy | 1991 |
Perinatal risk assessment for patent ductus arteriosus in premature infants.
Topics: Adolescent; Adult; Aspirin; Birth Weight; Ductus Arteriosus, Patent; Female; Histamine Antagonists; | 1986 |
Influence of acetylsalicylic acid, an inhibitor of prostaglandin synthesis, on the duration of human gestation and labour.
Topics: Adult; Aspirin; Birth Weight; Female; Humans; Infant, Newborn; Labor, Obstetric; Postpartum Hemorrha | 1973 |